Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885698 · ClinicalTrials.gov registry record
MYLUNG Consortium Part 3: Observational Study
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by US Oncology Research.
- Recruiting
- Registry status
- 7,500
- Enrollment target
- 17
- Study locations
NCT05885698: Recruiting study of Carcinoma, Non-Small Cell Lung, sponsored by US Oncology Research.
NCT05885698 is a study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by US Oncology Research. The registered enrollment target is 7,500 participants, above the 266-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (2720% higher). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05885698, a study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by US Oncology Research.
- RECRUITING
- Registry status
- 7,500 participants
- Enrollment target
- 17
- Study locations
Study Summary
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Conditions Studied
Study Locations (17)
Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Blacksburg
- Virginia Cancer Specialists, PC - Fairfax
- Virginia Oncology Associates - Newport News
- Shenandoah Oncology, P.C. - Winchester
Florida
- Cancer Care Centers of Brevard, Inc. - Palm Bay
- Woodlands Medical Specialists, PA - Pensacola
Illinois
- Affiliated Oncologists, LLC - Chicago Ridge
- Illinois Cancer Specialists - Niles
Alabama
- Southern Cancer Center, PC - Daphne
Arizona
- Arizona Oncology Associates, PC - NAHOA - Prescott Valley
Colorado
- Rocky Mountain Cancer Center - Denver
Maryland
- Maryland Oncology Hematology, P.A. - Silver Spring
Minnesota
- Minnesota Oncology Hematology, P.A. - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,500 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2030-12 |
What NCT05885698 shows while recruiting
NCT05885698 is an observational study that tracks outcomes without assigning an intervention. Its 7,500 participants enrollment target places it among the larger protocols in the corpus, above the 266-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (2720% higher).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.
NCT05885698 lists 17 locations in 12 states (Virginia, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT05885698 about?
NCT05885698 is a clinical study titled "MYLUNG Consortium Part 3: Observational Study". This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or n...
What is the current status of trial NCT05885698?
This trial is currently recruiting. The enrollment target is 7,500 participants. The study started on 2023-01-30. Estimated completion is 2030-12.
What conditions does trial NCT05885698 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
Who is sponsoring clinical trial NCT05885698?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05885698 being conducted?
This trial has 17 study locations across Alabama, Arizona, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05885698's enrollment target sits among peer trials
7,500 1st of 130 higher than 130 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
- NCT06112418 · 7,500 participants · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI